Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Completed · Phase 1/Phase 2

Conditions studied: HNSCC

In brief

This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.

Key facts

Study ID: NCT04997902
Run by: Kura Oncology, Inc.
People needed: 45
Starts: 2021-12-07
Expected to finish: 2025-08-29
Last updated by the study team: 2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

At least 18 years of age.
Histologically confirmed head and neck cancer of squamous histology not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
Documented treatment failure from at least 1 prior systemic therapy in the R/M setting, unless determined not appropriate.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Has a tumor that is dependent upon HRAS and/or PIK3CA.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Acceptable liver, renal, endocrine, and hematologic function.
Must be able to swallow alpelisib whole tablet or oral suspension containing crushed tablets. Feeding tube may not be used for alpelisib administration.
Other protocol defined inclusion criteria may apply.

You may not qualify if…

Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or nonsquamous histologies (eg, mucosal melanoma).
Ongoing treatment with certain anticancer agents.
Prior treatment (at least 1 full treatment cycle) with an FTI or PI3K, mTOR, or AKT inhibitor.
Received treatment for unstable angina, myocardial infarction, and/or cerebro-vascular attack within the prior 6 months.
Non-tolerable Grade 2, or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.
Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
Participant with an established diagnosis of diabetes mellitus Type 1 or not controlled Type 2.
Participant has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the trial drugs based on Investigator discretion.
Participant has currently documented pneumonitis/interstitial lung disease.
Participant has a history of severe cutaneous reaction, such as Stevens-Johnson Syndrome (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Other protocol defined exclusion criteria may apply.

Where it is running

City of Hope Comprehensive Cancer Center — Duarte, California, United States
Lake Nona DDU (Florida Cancer Specialists) — Orlando, Florida, United States
University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center) — Baltimore, Maryland, United States
Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center) — Baltimore, Maryland, United States
Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center) — Boston, Massachusetts, United States
Washington University, School of Medicine — St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center) — Dallas, Texas, United States
University of Texas MD Anderson Cancer Center — Houston, Texas, United States
University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.